Results 111 to 120 of about 81,917 (261)
AI‐Driven Rational Design of Nanotherapeutics for Pancreatic Ductal Adenocarcinoma
ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains a formidable malignancy characterized by late diagnosis, high recurrence rates, and pronounced chemoresistance. While nanoparticle‐based drug delivery systems (NDDS) offer theoretical advantages over conventional therapies, their clinical translation in PDAC has been severely limited.
Seohyun Choo +4 more
wiley +1 more source
SHP2 in Cancer: From Tumor Biology to Therapeutic Targeting
ABSTRACT SHP2 is a tyrosine phosphatase that mediates intracellular signaling downstream of transmembrane receptors regulated by a pair of src homology 2 (SH2) domains. Its overexpression and mutation are pivotal in driving tumor progression by influencing various cancer's fundamental characteristics, such as metastasis, DNA repair, angiogenesis ...
Maryam Jama +2 more
wiley +1 more source
Cardiac Monitoring for Patients Undergoing Treatment With MEK Inhibitor Monotherapy. [PDF]
Menteer J +5 more
europepmc +1 more source
Abstract Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor originating from calcitonin producing C‐cells and accounts for 1–5% of thyroid cancers. Total thyroidectomy is curative in localized disease (N0), whereas lymph node metastases (N1) are associated with poorer prognosis.
Anna Citarella +24 more
wiley +1 more source
Significant resolution of multiple adult-onset xanthogranulomas with MEK inhibitor therapy. [PDF]
Wang X +5 more
europepmc +1 more source
Chronic Pruritic Papular Eruption in an Elderly Man
JEADV Clinical Practice, EarlyView.
Filipe Monteiro +6 more
wiley +1 more source
ABSTRACT Type 2 diabetes mellitus (T2DM), characterized by insulin resistance, is closely associated with Alzheimer's disease (AD). Cerebrovascular dysfunction is manifested in both T2DM and AD, and is often considered as a pathological link between the two diseases.
Zengtao Wang +6 more
wiley +1 more source
MEK inhibitor-based genomically matched combinatorial targeted therapies in metastatic pancreatic adenocarcinoma with KRAS alterations. [PDF]
Auckley ED +11 more
europepmc +1 more source

